Iambic Therapeutics sets $15 to $17 range for its $150 million Nasdaq IPO
As seen on the 24/7 Wall St. homepage on October 8, 2026.
Iambic sets $15-$17 range for $150 million Nasdaq IPO
Iambic Therapeutics put a price on its Nasdaq debut, about $150 million raised at $15 to $17 per share. Pricing is the last step before the AI drug discovery name starts trading.
Continue ReadingShow less
Iambic Therapeutics has filed an amended prospectus with the SEC setting a price range of $15 to $17 per share for its Nasdaq listing, an offering that would raise roughly $150 million for an AI-focused drug discovery company.
With the range now on file, Iambic moves into the roadshow and book-building phase, after which underwriters will price the deal and shares can begin trading on Nasdaq.
The window between a final price range amendment and the first day of trading is typically short, so the timeline for taking a position is narrowing.
The offering details come from an amended SEC filing dated October 8, 2026, and no final price has been set, so the range remains subject to adjustment before the deal closes.